Apogem Capital LLC Aldeyra Therapeutics, Inc. Transaction History

Apogem Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $244,172 - $497,341	-64,256 Reduced 43.02%	85,091 $454,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $110,091 - $219,729	45,305 Added 43.54%	149,347 $596,000
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $56,264 - $89,503	17,312 Added 19.96%	104,042 $462,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $105,269 - $289,641	30,077 Added 53.09%	86,730 $347,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $86,720 - $123,527	10,922 Added 23.88%	56,653 $497,000
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $98,355 - $139,901	9,421 Added 25.95%	45,731 $518,000
Q1 2021 May 14, 2021	SELL	$6.53 - $14.42 $127,406 - $281,348	-19,511 Reduced 34.95%	36,310 $431,000
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $352,230 - $453,824	55,821 New	55,821 $383,000

122

36.7M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $345M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.